Thoracic Stop-Flow Perfusion in the Treatment of Refractory Non Small Cell Lung Cancer

被引：7

作者：

Guadagni, S. ^{[1
]}

Mueller, H. ^{[2
]}

Valenti, M. ^{[3
]}

Clementi, M. ^{[1
]}

Fiorentini, G. ^{[4
]}

Cantore, M. ^{[5
]}

Amicucci, G. ^{[1
]}

机构：

[1] Univ Aquila, Dept Surg Sci, I-67100 Laquila, Italy

[2] Carl von Hess Hosp, Dept Oncol Surg, Hammelburg, Germany

[3] Univ Aquila, Dept Med Stat, Laquila, Italy

[4] USL Empoli, Dept Oncol, Empoli, Italy

[5] USL Massa Carrara, Dept Oncol, Carrara, Italy

来源：

JOURNAL OF CHEMOTHERAPY | 2004年 / 16卷

关键词：

Non small cell lung cancer; thoracic perfusion; stop flow; regional chemotherapy; systemic chemotherapy;

D O I：

10.1080/1120009X.2004.11782382

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This study was undertaken to determine the survival of patients with unresectable and refractory non small cell lung cancer (NSCLC) submitted to thoracic stop-flow perfusion (TSP). Forty-five patients with NSCLC confined to thoracic region entered the study. All 45 patients had been pretreated with some form of chemotherapy and had progression of disease. The cytostatic regimen was mitomycin 10 mg/m(2), navelbine 25 mg/m(2) and cisplatin 60 mg/m(2). In 39/45 patients, immediately after TSP, hemofiltration was performed to reduce systemic side effects There were 16/45 responses to the first TSP (CR 0; PR 16): a response rate of 35.6%. Median time to progression was 4 months. Median survival was 7.5 months. 1-year survival rate was 36.4%, 2-year survival rate was 14%, and 3-year survival rate was 5.7%.

引用

页码：40 / 43

页数：4

共 11 条

[1]

Fossella FV, 1997, SEMIN ONCOL, V24, P455

[2] Cytostatic lung perfusion by use of an endovascular blood flow occlusion technique [J].